Cargando…

Short-Term Effects of Verapamil and Diltiazem in the Treatment of No Reflow Phenomenon: A Meta-Analysis of Randomized Controlled Trials

Currently, there is still a lack of an optimal treatment for no reflow phenomenon (NRP). We analyzed the efficacy and safety of using nondihydropyridine calcium channel antagonists (NDHP, verapamil/diltiazem) in patients suffering from NRP. Eight RCTs with 494 participants were eligible for analysis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Lan, Cheng, Zhong, Gu, Ye, Peng, Dingfeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2015
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4609355/ https://www.ncbi.nlm.nih.gov/pubmed/26504804 http://dx.doi.org/10.1155/2015/382086

Ejemplares similares

Effects of Verapamil and Diltiazem on the Pharmacokinetics and Pharmacodynamics of Rivaroxaban
por: Kim, Minsoo, et al.
Publicado: (2019)

Meta-analysis of randomized controlled trials on the efficacy and safety of intracoronary administration of tirofiban for no-reflow phenomenon
por: Qin, Tao, et al.
Publicado: (2013)

No-Reflow Phenomenon and Endothelial Glycocalyx of Microcirculation
por: Maksimenko, Alexander V., et al.
Publicado: (2012)

“No-Reflow” Phenomenon: A Contemporary Review
por: Annibali, Gianmarco, et al.
Publicado: (2022)

Amiodarone, Verapamil, or Diltiazem Use With Direct Oral Anticoagulants and the Risk of Hemorrhage in Older Adults
por: Hill, Kevin, et al.
Publicado: (2021)

Rate control with intravenous diltiazem, verapamil, and metoprolol in acute atrial fibrillation with rapid ventricular rate
por: Medeiros, Tia, et al.
Publicado: (2021)

A Randomized, Single-Center Double-Blinded Trial on the Effects of Diltiazem Sustained-Release Capsules in Patients with Coronary Slow Flow Phenomenon at 6-Month Follow-Up
por: Li, Lun, et al.
Publicado: (2012)

Plasma calprotectin was associated with platelet activation and no-reflow phenomenon in acute coronary syndrome
por: Song, Nian-Peng, et al.
Publicado: (2020)

Non-pharmaco, non-invasive management of coronary no-reflow phenomenon
por: Sinha, Santosh Kumar, et al.
Publicado: (2020)

The No-reflow Phenomenon: Is it Predictable by Demographic factors and Routine Laboratory Data?
por: Namazi, Mohammadhasan, et al.
Publicado: (2021)

Association of Oral Anticoagulants and Verapamil or Diltiazem With Adverse Bleeding Events in Patients With Nonvalvular Atrial Fibrillation and Normal Kidney Function
por: Pham, Phuong, et al.
Publicado: (2020)

Intravascular Ultrasound Observation of the Mechanism of No-Reflow Phenomenon in Acute Myocardial Infarction
por: Li, Junxia, et al.
Publicado: (2015)

A Narrative Review of the Classical and Modern Diagnostic Methods of the No-Reflow Phenomenon
por: Pantea-Roșan, Larisa Renata, et al.
Publicado: (2022)

Effects of L-type Calcium Channel Antagonists Verapamil and Diltiazem on fKv1.4ΔN Currents in Xenopus oocytes
por: Chen, Hui, et al.
Publicado: (2013)

No reflow phenomenon in percutaneous coronary interventions in ST-segment elevation myocardial infarction
por: Gupta, Sanjiv, et al.
Publicado: (2016)

The SALINE Technique for the Treatment of the No-Reflow Phenomenon during Percutaneous Coronary Intervention in STEMI
por: Grancini, Luca, et al.
Publicado: (2023)

Mechanisms of the “No-Reflow” Phenomenon After Acute Myocardial Infarction: Potential Role of Pericytes
por: Kaul, Sanjiv, et al.
Publicado: (2022)

No-Reflow Phenomenon in Central Retinal Artery Occlusion: Incidence, Risk Factors, and Clinical Implications
por: Ahn, Seong Joon, et al.
Publicado: (2015)

Correlates of the “No-Reflow” or “Slow-Flow” Phenomenon in Patients Undergoing Primary Percutaneous Coronary Intervention
por: Alidoosti, Mohammad, et al.
Publicado: (2018)

No-reflow phenomenon and in vivo cholesterol crystals combined with lipid core in acute myocardial infarction()
por: Katayama, Yosuke, et al.
Publicado: (2022)

MELD-XI score predict no-reflow phenomenon and short-term mortality in patient with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention
por: Zhang, Xin-Tao, et al.
Publicado: (2022)

No-Reflow after PPCI—A Predictor of Short-Term Outcomes in STEMI Patients
por: Pantea-Roșan, Larisa Renata, et al.
Publicado: (2020)

The predictors of no reflow phenomenon after percutaneous coronary intervention in patients with ST elevation myocardial infarction: A meta-analysis
por: Fajar, Jonny Karunia, et al.
Publicado: (2018)

No-Reflow Phenomenon During Treatment of Coronary In-Stent Restenosis With a Paclitaxel-Coated Balloon Catheter
por: Chung, Han-Hee, et al.
Publicado: (2012)

Delayed Treatment With Hypothermia Protects Against the No‐Reflow Phenomenon Despite Failure to Reduce Infarct Size
por: Hale, Sharon L., et al.
Publicado: (2013)

Evaluation of the Clinical and Procedural Predictive Factors of no-Reflow Phenomenon Following Primary Percutaneous Coronary Intervention
por: Abdi, Seifollah, et al.
Publicado: (2015)

hsCRP and ET-1 expressions in patients with no-reflow phenomenon after Percutaneous Coronary Intervention
por: Liu, Min, et al.
Publicado: (2017)

The role of SCUBE1 in the pathogenesis of no-reflow phenomenon presenting with ST segment elevation myocardial infarction
por: Bolayır, Hasan Ata, et al.
Publicado: (2017)

Factors associated with the no-reflow phenomenon following percutaneous intervention of saphenous vein coronary bypass grafts
por: Hashemi-Jazi, Mohammad, et al.
Publicado: (2017)

No-reflow phenomenon in acute myocardial infarction: Relieve pressure from the procedure and focus attention to the patient
por: Buono, Andrea, et al.
Publicado: (2019)

Calcified plaque harboring lipidic materials associates with no-reflow phenomenon after PCI in stable CAD
por: Hosoda, Hayato, et al.
Publicado: (2023)

Prophylactically injection of Nicorandil to reduce no-reflow phenomenon during PCI in acute STEMI patients: Protocol of a double-blinded, randomized, placebo-controlled trial
por: An, Su, et al.
Publicado: (2021)

Safety and Efficacy of Prehospital Diltiazem
por: Luk, Jeffrey H., et al.
Publicado: (2013)

Diltiazem-associated Photodistributed Hyperpigmentation
por: Siegel, Jacob D., et al.
Publicado: (2020)

Comparison of no-reflow phenomenon after percutaneous coronary intervention for acute myocardial infarction between smokers and nonsmokers
por: Shemirani, Hassan, et al.
Publicado: (2014)

No-reflow phenomenon during percutaneous coronary intervention in a patient with polycythemia vera: A case report
por: Oktaviono, Yudi Her, et al.
Publicado: (2020)

Effect of intracoronary agents on the no-reflow phenomenon during primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction: a network meta-analysis
por: Niu, Xiaowei, et al.
Publicado: (2018)

Serum cystatin C levels relate to no-reflow phenomenon in percutaneous coronary interventions in ST-segment elevation myocardial infarction
por: Cheng, Chao, et al.
Publicado: (2019)

Pseudo-no-Reflow Phenomenon in Carotid Artery Stenting using FilterWire EX: Successful Recovery by Aspiration Thrombectomy
por: Han, Seung Hwan, et al.
Publicado: (2009)

Prediction of no-reflow phenomenon in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction
por: Yang, Li, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_slhjlpn76rs47ttufpoc9s0nhb